SCHEMBL6824243

SCHEMBL6824243

Clc1cccc(Cn2ccc3cc(Cl)ccc32)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 3/20 0.54
PLG P00747 2/20 0.54
EGFR P00533 1/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
DBH P09172 1/20 0.51
KDM4E B2RXH2 1/20 0.50
TP53 P04637 1/20 0.50
MAPT P10636 1/20 0.50
HTR6 P50406 1/20 0.50
EGLN1 Q9GZT9 1/20 0.50
LMNA P02545 2/20 0.49
POLB P06746 1/20 0.49
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
NR1I2 O75469 1/20 0.47
HDAC3 O15379 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824300 0.92 APP (0.55) PLAUPLGHTR2AHTR2CHTR6
SCHEMBL14854852 0.90 EGFR (0.62) PLAUPLGEGFRHTR2AHTR2C
SCHEMBL6085311 0.89 HTR6 (0.59) PLAUDBHKDM4ETP53MAPT
SCHEMBL30218818 0.89 HTR6 (0.59) PLAUDBHKDM4ETP53MAPT
SCHEMBL6087507 0.88 HDAC8 (0.57) PLAUPLGHTR2AHTR2CTP53
SCHEMBL6085843 0.86 ALDH1A1 (0.50) PLAUPLGEGFRDBHKDM4E
SCHEMBL28470081 0.86 NPC1 (0.54) PLAUPLGEGFRDBHKDM4E
SCHEMBL13802415 0.85 PLAU (0.56) PLAUPLGKDM4EHDAC3HDAC1
SCHEMBL9198838 0.82 HTR2A (0.51) PLAUPLGEGFRHTR2AHTR2C
SCHEMBL6085382 0.82 HDAC3 (0.54) PLAUPLGHTR2AHTR2CMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R PLAU 3998/4885PLG 2678/4885EGFR 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.